- What changed in KLRS news today?
- Kalaris Q3 loss narrows to $11.03 million as TH103 data shift to 2027: Kalaris Therapeutics’ third-quarter 2026 net loss narrowed 7% year over year to $11.03 million, with operating expenses at $11.81 million. A supply interruption delayed preliminary TH103 Phase 1b/2 data in nAMD to the second half of 2027; cash is expected to fund operations into 2028.
- Does Rallies summarize KLRS news?
- Yes. Rallies summarizes KLRS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is KLRS research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for KLRS. It does not provide personalized investment advice.
